AI in Clinical Trials: How Machine Learning Is Transforming Drug Development
Clinical trials have a reputation for being slow, expensive, and full of paperwork. Machine learning is one of the biggest reasons that reputation is changing. The Clarity Clinical Solutions video "AI in Clinical Trials: How Machine Learning Is Transforming Drug Development" walks through where AI already works in trials, from recruitment to safety monitoring, and why regulators are paying close attention.
The short version: AI is not replacing clinical researchers. But trials that use AI well are getting faster, and the people who run them are getting ahead.
Where AI fits in a trial
Modern trials generate enormous amounts of data. Genomic sequencing, wearable sensors, electronic health records, scan images. The video makes the point that AI is often the only practical way to make sense of all of it.
A few examples from the video:
- Machine learning models identify biomarkers that predict how a patient will respond to a drug.
- Computer vision reads medical scans faster and more consistently than human readers.
- Natural language processing pulls insights out of unstructured nurse and doctor notes.
- AI analyzes continuous streams from smartwatches and fitness trackers.
In safety monitoring, AI can watch lab values and vital signs in real time, spot patterns that precede adverse events, and flag combinations of symptoms a human reviewer might miss. The video claims this can surface safety signals up to two weeks earlier than traditional statistical methods. That is the kind of lead time that saves lives in a large trial.
Recruitment: the bottleneck AI attacks first
Patient recruitment is one of the most expensive bottlenecks in drug development. The video cites a figure that has been around the industry for years: up to 80% of trials fail to enroll on time.
AI attacks this problem directly. Natural language processing scans electronic health records and matches patients to trial criteria automatically. Predictive models identify patients who are likely to consent and stay in the study. Eligibility screening can happen in real time at the point of care, and automated outreach contacts potential participants immediately.
The video reports that AI-assisted screening enrolls patients about three times faster and cuts manual chart review time by 80%. Those specific numbers come from the video and are worth treating as estimates, but the direction is well established: sponsors and contract research organizations are investing heavily in AI-driven patient matching.
AI can also forecast whether a protocol will succeed before it launches. In one case study described in the video, a model trained on thousands of past trials predicted with 76% accuracy whether a phase 2 drug would survive phase 3. Being able to kill a failing program early saves sponsors millions of dollars, and AI models are also used to predict dropout rates by site and spot protocol design flaws before the first patient is enrolled.
Smarter protocols, fewer amendments
Designing a protocol takes months of expert consultation. AI can accelerate that. The video lists applications such as generating protocol drafts from past studies, optimizing inclusion and exclusion criteria, suggesting endpoints and biomarkers, and identifying dose ranges from preclinical data.
The payoff is fewer amendments. Each protocol amendment is expensive, and the video puts the average cost at about $500,000 with months of delay attached. Get the design right up front, and the whole program moves faster.
Synthetic control arms: the ethical upgrade
One of the most interesting applications is the synthetic control arm. Instead of giving some participants a placebo, AI builds a virtual comparison group from historical patient data, matching current trial patients to similar patients treated in earlier studies.
The advantages are real: fewer patients needed, faster enrollment, and every participant receives active treatment, which is a meaningful ethical improvement. The FDA has accepted synthetic control arm data in some drug approval decisions, and the agency's broader real-world evidence program is the umbrella under which these analyses are developing.
What regulators are doing
Regulators are not watching from the sidelines. In January 2025 the FDA issued its first draft guidance on using AI in drug and biological product development, Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products. The document lays out how sponsors should think about credibility of AI models, data governance, and documentation.
On the device side, the FDA maintains a public list of AI/ML-enabled medical devices that have been authorized, and the number has grown quickly over the past decade. The video mentions that the FDA has approved more than 700 AI-enabled devices; the agency's published count has since climbed past a thousand.
The European Medicines Agency published an artificial intelligence work plan covering 2025 to 2027, and the International Council for Harmonisation is considering how AI should appear in good clinical practice guidance. The video attributes those developments to the EMA and ICH directly, and you can track the EMA's broader regulatory science priorities on its regulatory science strategy page. The ICH's ongoing work on efficacy guidelines, including E6(R3) on good clinical practice, is the most likely home for formal AI guidance.
The open problems
The video is honest about what still blocks wider adoption. Four challenges stand out:
- Algorithm transparency and explainability. If a model flags a safety signal, regulators and investigators need to understand why.
- Data privacy and security. Training and running models on patient data requires careful handling of identifiable information.
- Algorithmic bias. A model trained on one population may perform badly in another, which is a direct threat to health equity.
- Validation and reproducibility. Models need rigorous testing with fixed versions and reproducible outputs before anyone can rely on them in a regulatory submission.
These are not solved problems. They are the reason the FDA's draft guidance leans heavily on model credibility and lifecycle management rather than simply blessing AI as a tool.
The bottom line
AI is already inside clinical trials, and the video's closing line is the one worth remembering: AI will not replace clinical researchers, but researchers who use AI will replace those who do not. From faster recruitment to real-time safety monitoring to synthetic control arms, the direction of travel is clear. The trials that get the regulatory, data, and validation questions right will be the ones that run faster, cheaper, and more safely.
This article is based on the Clarity Clinical Solutions video "AI in Clinical Trials: How Machine Learning Is Transforming Drug Development." Watch it here: AI in Clinical Trials: How Machine Learning Is Transforming Drug Development
References
- Clarity Clinical Solutions — "AI in Clinical Trials: How Machine Learning Is Transforming Drug Development" (source video; recruitment, protocol design, synthetic control arms, and regulatory sections). https://www.youtube.com/watch?v=aC0dhlEkOeE
- FDA draft guidance — Considerations for the Use of Artificial Intelligence to Support Regulatory Decision-Making for Drug and Biological Products (supports the regulators' framework discussion). https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological
- FDA — Artificial Intelligence and Machine Learning (AI/ML)-Enabled Medical Devices (supports the AI-enabled device count discussion). https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices
- FDA — Real-World Evidence (supports the synthetic control arms discussion). https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence
- EMA — Regulatory Science Strategy (supports the EMA AI priorities discussion). https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-strategy
- ICH — Efficacy Guidelines (supports the ICH good clinical practice discussion). https://www.ich.org/page/efficacy-guidelines